Global Endometriosis Treatment Market

Endometriosis Treatment Comprehensive Study by Type (Gonadotropins releasing hormone agonists, Progestin, Non-steroidal anti-inflammatory drugs, Oral contraceptive pills), Application (Hospital pharmacies, Drug stores, Mail order pharmacies, Retail pharmacies, E-commerce, Others) Players and Region - Global Market Outlook to 2029

Endometriosis Treatment Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Endometriosis TreatmentMarket?
Endometriosis treatment is done when the tissue which makes the uterine lining is present on other organ in human body. It can occur in any part of the body, but found mostly in lower abdomen or pelvis area.

Endometriosis Treatment Market Report Coverage
Report CoverageDetails
Study Timeframe2019 to 2029
Base Year2023
Growth Drivers
  • Recurrence of Endometriosis
  • Rising Adoption of Oral Contraceptive Pill
Challenges & Pitfalls
  • Lack of Proper Diagnostic Tools
  • High Cost of Trearment


Opportunities
Growing Cases of Endometriosis and Rising Healthcare Budget

Restraints
  • Availability of Alternative Treatment Methods such as Intrauterine Systems (IUS)
  • Potential Adverse Effect of Treatment on Human Body


The Players Covered in the Study are:
Eli lilly [United States], Astrazeneca [United Kingdom], Bayer ag [Germany], Astellas pharma [Japan], Abbvie [United States], Meditrina pharmaceuticals [United States], Pfizer [United States], Neurocrine biosciences [United States] and Takeda pharmaceutical [Japan]

Available Customization:
A list of players that can be included in the study on an immediate basis are Merck & Co [United States], Novartis [Switzerland], Gilead Sciences [United States] and GlaxoSmithKline [United Kingdom].


Market Development Activities
In July , 2018 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved ORILISSA™ (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.1,2 The FDA approved ORILISSA under priority review

In January 2022,Cromwell Hospital has launched a new international centre to help women get a diagnosis and treatment for endometriosis. and Endometriosis is a condition where the cells, similar to those that create the womb’s lining, grow elsewhere in the body, such as on the fallopian tubes. These cells react to the monthly menstrual cycle and bleed, but as there is no way for the blood to leave the body, it can cause inflammation, pain and scarring

Report Objectives / Segmentation Covered

By Type
  • Gonadotropins releasing hormone agonists
  • Progestin
  • Non-steroidal anti-inflammatory drugs
  • Oral contraceptive pills
By Application
  • Hospital pharmacies
  • Drug stores
  • Mail order pharmacies
  • Retail pharmacies
  • e-commerce
  • others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Recurrence of Endometriosis
      • 3.2.2. Rising Adoption of Oral Contraceptive Pill
    • 3.3. Market Challenges
      • 3.3.1. Lack of Proper Diagnostic Tools
      • 3.3.2. High Cost of Trearment
    • 3.4. Market Trends
      • 3.4.1. Replacement of GnRH (Gonadotropin-releasing Hormone) Agonists
      • 3.4.2. Rising focus on IUDs (Intrauterine Devices)
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Endometriosis Treatment, by Type, Application and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Endometriosis Treatment (Value)
      • 5.2.1. Global Endometriosis Treatment by: Type (Value)
        • 5.2.1.1. Gonadotropins releasing hormone agonists
        • 5.2.1.2. Progestin
        • 5.2.1.3. Non-steroidal anti-inflammatory drugs
        • 5.2.1.4. Oral contraceptive pills
      • 5.2.2. Global Endometriosis Treatment by: Application (Value)
        • 5.2.2.1. Hospital pharmacies
        • 5.2.2.2. Drug stores
        • 5.2.2.3. Mail order pharmacies
        • 5.2.2.4. Retail pharmacies
        • 5.2.2.5. E-commerce
        • 5.2.2.6. Others
      • 5.2.3. Global Endometriosis Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Endometriosis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Eli lilly [United States]
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Astrazeneca [United Kingdom]
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer ag [Germany]
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Astellas pharma [Japan]
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Abbvie [United States]
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Meditrina pharmaceuticals [United States]
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer [United States]
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Neurocrine biosciences [United States]
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Takeda pharmaceutical [Japan]
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Endometriosis Treatment Sale, by Type, Application and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Endometriosis Treatment (Value)
      • 7.2.1. Global Endometriosis Treatment by: Type (Value)
        • 7.2.1.1. Gonadotropins releasing hormone agonists
        • 7.2.1.2. Progestin
        • 7.2.1.3. Non-steroidal anti-inflammatory drugs
        • 7.2.1.4. Oral contraceptive pills
      • 7.2.2. Global Endometriosis Treatment by: Application (Value)
        • 7.2.2.1. Hospital pharmacies
        • 7.2.2.2. Drug stores
        • 7.2.2.3. Mail order pharmacies
        • 7.2.2.4. Retail pharmacies
        • 7.2.2.5. E-commerce
        • 7.2.2.6. Others
      • 7.2.3. Global Endometriosis Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Endometriosis Treatment: by Type(USD Million)
  • Table 2. Endometriosis Treatment Gonadotropins releasing hormone agonists , by Region USD Million (2018-2023)
  • Table 3. Endometriosis Treatment Progestin , by Region USD Million (2018-2023)
  • Table 4. Endometriosis Treatment Non-steroidal anti-inflammatory drugs , by Region USD Million (2018-2023)
  • Table 5. Endometriosis Treatment Oral contraceptive pills , by Region USD Million (2018-2023)
  • Table 6. Endometriosis Treatment: by Application(USD Million)
  • Table 7. Endometriosis Treatment Hospital pharmacies , by Region USD Million (2018-2023)
  • Table 8. Endometriosis Treatment Drug stores , by Region USD Million (2018-2023)
  • Table 9. Endometriosis Treatment Mail order pharmacies , by Region USD Million (2018-2023)
  • Table 10. Endometriosis Treatment Retail pharmacies , by Region USD Million (2018-2023)
  • Table 11. Endometriosis Treatment E-commerce , by Region USD Million (2018-2023)
  • Table 12. Endometriosis Treatment Others , by Region USD Million (2018-2023)
  • Table 13. South America Endometriosis Treatment, by Country USD Million (2018-2023)
  • Table 14. South America Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 15. South America Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 16. Brazil Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 17. Brazil Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 18. Argentina Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 19. Argentina Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 20. Rest of South America Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 21. Rest of South America Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 22. Asia Pacific Endometriosis Treatment, by Country USD Million (2018-2023)
  • Table 23. Asia Pacific Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 24. Asia Pacific Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 25. China Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 26. China Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 27. Japan Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 28. Japan Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 29. India Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 30. India Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 31. South Korea Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 32. South Korea Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 33. Taiwan Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 34. Taiwan Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 35. Australia Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 36. Australia Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 37. Rest of Asia-Pacific Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 38. Rest of Asia-Pacific Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 39. Europe Endometriosis Treatment, by Country USD Million (2018-2023)
  • Table 40. Europe Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 41. Europe Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 42. Germany Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 43. Germany Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 44. France Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 45. France Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 46. Italy Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 47. Italy Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 48. United Kingdom Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 49. United Kingdom Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 50. Netherlands Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 51. Netherlands Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 52. Rest of Europe Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 53. Rest of Europe Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 54. MEA Endometriosis Treatment, by Country USD Million (2018-2023)
  • Table 55. MEA Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 56. MEA Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 57. Middle East Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 58. Middle East Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 59. Africa Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 60. Africa Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 61. North America Endometriosis Treatment, by Country USD Million (2018-2023)
  • Table 62. North America Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 63. North America Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 64. United States Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 65. United States Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 66. Canada Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 67. Canada Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 68. Mexico Endometriosis Treatment, by Type USD Million (2018-2023)
  • Table 69. Mexico Endometriosis Treatment, by Application USD Million (2018-2023)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Endometriosis Treatment: by Type(USD Million)
  • Table 80. Endometriosis Treatment Gonadotropins releasing hormone agonists , by Region USD Million (2024-2029)
  • Table 81. Endometriosis Treatment Progestin , by Region USD Million (2024-2029)
  • Table 82. Endometriosis Treatment Non-steroidal anti-inflammatory drugs , by Region USD Million (2024-2029)
  • Table 83. Endometriosis Treatment Oral contraceptive pills , by Region USD Million (2024-2029)
  • Table 84. Endometriosis Treatment: by Application(USD Million)
  • Table 85. Endometriosis Treatment Hospital pharmacies , by Region USD Million (2024-2029)
  • Table 86. Endometriosis Treatment Drug stores , by Region USD Million (2024-2029)
  • Table 87. Endometriosis Treatment Mail order pharmacies , by Region USD Million (2024-2029)
  • Table 88. Endometriosis Treatment Retail pharmacies , by Region USD Million (2024-2029)
  • Table 89. Endometriosis Treatment E-commerce , by Region USD Million (2024-2029)
  • Table 90. Endometriosis Treatment Others , by Region USD Million (2024-2029)
  • Table 91. South America Endometriosis Treatment, by Country USD Million (2024-2029)
  • Table 92. South America Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 93. South America Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 94. Brazil Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 95. Brazil Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 96. Argentina Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 97. Argentina Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 98. Rest of South America Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 99. Rest of South America Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 100. Asia Pacific Endometriosis Treatment, by Country USD Million (2024-2029)
  • Table 101. Asia Pacific Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 102. Asia Pacific Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 103. China Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 104. China Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 105. Japan Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 106. Japan Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 107. India Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 108. India Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 109. South Korea Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 110. South Korea Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 111. Taiwan Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 112. Taiwan Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 113. Australia Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 114. Australia Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 115. Rest of Asia-Pacific Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 116. Rest of Asia-Pacific Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 117. Europe Endometriosis Treatment, by Country USD Million (2024-2029)
  • Table 118. Europe Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 119. Europe Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 120. Germany Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 121. Germany Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 122. France Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 123. France Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 124. Italy Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 125. Italy Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 126. United Kingdom Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 127. United Kingdom Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 128. Netherlands Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 129. Netherlands Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 130. Rest of Europe Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 131. Rest of Europe Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 132. MEA Endometriosis Treatment, by Country USD Million (2024-2029)
  • Table 133. MEA Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 134. MEA Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 135. Middle East Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 136. Middle East Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 137. Africa Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 138. Africa Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 139. North America Endometriosis Treatment, by Country USD Million (2024-2029)
  • Table 140. North America Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 141. North America Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 142. United States Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 143. United States Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 144. Canada Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 145. Canada Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 146. Mexico Endometriosis Treatment, by Type USD Million (2024-2029)
  • Table 147. Mexico Endometriosis Treatment, by Application USD Million (2024-2029)
  • Table 148. Research Programs/Design for This Report
  • Table 149. Key Data Information from Secondary Sources
  • Table 150. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Endometriosis Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Endometriosis Treatment: by Application USD Million (2018-2023)
  • Figure 6. South America Endometriosis Treatment Share (%), by Country
  • Figure 7. Asia Pacific Endometriosis Treatment Share (%), by Country
  • Figure 8. Europe Endometriosis Treatment Share (%), by Country
  • Figure 9. MEA Endometriosis Treatment Share (%), by Country
  • Figure 10. North America Endometriosis Treatment Share (%), by Country
  • Figure 11. Global Endometriosis Treatment share by Players 2023 (%)
  • Figure 12. Global Endometriosis Treatment share by Players (Top 3) 2023(%)
  • Figure 13. Global Endometriosis Treatment share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Eli lilly [United States] Revenue, Net Income and Gross profit
  • Figure 16. Eli lilly [United States] Revenue: by Geography 2023
  • Figure 17. Astrazeneca [United Kingdom] Revenue, Net Income and Gross profit
  • Figure 18. Astrazeneca [United Kingdom] Revenue: by Geography 2023
  • Figure 19. Bayer ag [Germany] Revenue, Net Income and Gross profit
  • Figure 20. Bayer ag [Germany] Revenue: by Geography 2023
  • Figure 21. Astellas pharma [Japan] Revenue, Net Income and Gross profit
  • Figure 22. Astellas pharma [Japan] Revenue: by Geography 2023
  • Figure 23. Abbvie [United States] Revenue, Net Income and Gross profit
  • Figure 24. Abbvie [United States] Revenue: by Geography 2023
  • Figure 25. Meditrina pharmaceuticals [United States] Revenue, Net Income and Gross profit
  • Figure 26. Meditrina pharmaceuticals [United States] Revenue: by Geography 2023
  • Figure 27. Pfizer [United States] Revenue, Net Income and Gross profit
  • Figure 28. Pfizer [United States] Revenue: by Geography 2023
  • Figure 29. Neurocrine biosciences [United States] Revenue, Net Income and Gross profit
  • Figure 30. Neurocrine biosciences [United States] Revenue: by Geography 2023
  • Figure 31. Takeda pharmaceutical [Japan] Revenue, Net Income and Gross profit
  • Figure 32. Takeda pharmaceutical [Japan] Revenue: by Geography 2023
  • Figure 33. Global Endometriosis Treatment: by Type USD Million (2024-2029)
  • Figure 34. Global Endometriosis Treatment: by Application USD Million (2024-2029)
  • Figure 35. South America Endometriosis Treatment Share (%), by Country
  • Figure 36. Asia Pacific Endometriosis Treatment Share (%), by Country
  • Figure 37. Europe Endometriosis Treatment Share (%), by Country
  • Figure 38. MEA Endometriosis Treatment Share (%), by Country
  • Figure 39. North America Endometriosis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Eli lilly [United States]
  • Astrazeneca [United Kingdom]
  • Bayer ag [Germany]
  • Astellas pharma [Japan]
  • Abbvie [United States]
  • Meditrina pharmaceuticals [United States]
  • Pfizer [United States]
  • Neurocrine biosciences [United States]
  • Takeda pharmaceutical [Japan]
Additional players considered in the study are as follows:
Merck & Co [United States] , Novartis [Switzerland] , Gilead Sciences [United States] , GlaxoSmithKline [United Kingdom] ,
Select User Access Type

Key Highlights of Report


Jan 2024 239 Pages 86 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Endometriosis Treatment Market Quantitative research analysis
Global Endometriosis Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Endometriosis Treatment market are Eli lilly [United States], Astrazeneca [United Kingdom], Bayer ag [Germany], Astellas pharma [Japan], Abbvie [United States], Meditrina pharmaceuticals [United States], Pfizer [United States], Neurocrine biosciences [United States] and Takeda pharmaceutical [Japan], to name a few.
"Replacement of GnRH (Gonadotropin-releasing Hormone) Agonists " is seen as one of major influencing trends for Endometriosis Treatment Market during projected period 2023-2029.
is dominating the Endometriosis Treatment Market.
The Endometriosis Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Endometriosis Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Pet Cancer Therapeutics Comprehensive Study by Type (Chemotherapy Drugs, Vaccines), Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary, Squamous Cell Cancer, Others), Treatment (Chemotherapy,...
$ 3450
Influenza Diagnostics Comprehensive Study by Type (Rapid Influenza Diagnostic Tests (RIDT), Direct Fluorescent Antibody (DFA) Tests, Molecular Diagnostic Tests, Traditional Diagnostic Tests, Viral Cu...
$ 3450
Prosthetic Heart Valves Comprehensive Study by Type (Transcatheter Heart Valve, Tissue Heart Valve, Mechanical Heart Valve), End User (Hospitals, Ambulatory Surgical Centers, Others) Players and Regi...
$ 3500
Cystoscope Comprehensive Study by Type (Rigid Cystoscope, Flexible Cystoscope), Application (Urology, Gynaecology), End User (Hospitals & Clinics, Ambulatory Surgical Centers) Players and Region - Gl...
$ 3500
Diuretics Comprehensive Study by Type (Thiazide diuretics, Loop diuretics, Potassium-sparing diuretics), Application (Hypertension, Edema, Hypercalciuria, Diabetes, Insipidus, Others), Distribution C...
$ 3750
Therapeutic Vaccines Comprehensive Study by Category (Antigen Vaccines, Dendritic Cell Vaccines, DNA Vaccines, Tumor Cell Vaccines), Disease (Autoimmune Disease, Cancer, Neurological Diseases, Infect...
$ 3650